Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy may beat stubborn fungal infections

NCT ID NCT07420894

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding isotretinoin (a retinoid that changes skin oil and growth) to the standard antifungal itraconazole works better than itraconazole alone for adults with resistant Trichophyton fungal skin infections. 148 adults aged 18-65 with confirmed infection were randomly assigned to one of two groups. The goal was to see if the combination leads to higher cure rates and fewer relapses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

148 people

The number who actually took part.

Started

Jan 2025

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 65 years * Clinical features suggestive of dermatophytosis * Laboratory-confirmed Trichophyton infection at baseline * Provision of written informed consent * Ability and willingness to comply with treatment, follow-up visits, and required laboratory monitoring Exclusion Criteria: * Negative potassium hydroxide microscopy and no culture evidence of Trichophyton infection at baseline * Infection caused by non-Trichophyton dermatophytes on culture, or no growth on culture where culture is used for confirmation * Use of additional systemic antifungal therapy during the treatment period (not permitted by protocol) * Use of systemic retinoids other than study-assigned isotretinoin during the treatment period (not permitted by protocol) * Pregnancy at baseline in women of childbearing potential, or inability or unwillingness to follow strict pregnancy avoidance requirements during and after isotretinoin therapy * Any contraindication to itraconazole or isotretinoin, including known hypersensitivity to either drug * Clinically significant baseline liver dysfunction or abnormal liver function tests considered unsafe for systemic itraconazole and or isotretinoin use

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dermatophytosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dermatophytosis Kerion celsi Tinea Trichophyton infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Multan Medical and Dental College

    Multan, Punjab Province, 60000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.